Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination

• Published in: International journal of molecular sciences Vol. 23; no. 22; p. 13675
• Main Authors: Quesada-Vázquez, Sergio, Bone, Caitlin, Saha, Shikha, Triguero, Iris, Colom-Pellicer, Marina, Aragonès, Gerard, Hildebrand, Falk, Del Bas, Josep M, Caimari, Antoni, Beraza, Naiara, Escoté, Xavier
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.11.2022; MDPI
• Subjects: Acetylcysteine; Animals; Carnitine; Cell proliferation; Cofactors; Cytokines; Digestive system; Dysbacteriosis; Dysbiosis; Epithelial cells; Epithelium; Fatty acids; Fatty Acids, Volatile - pharmacology; Fatty liver; Gastrointestinal Microbiome; Gene expression; Goblet cells; gut microbiota; gut-liver axis; Homeostasis; Immune system; Inflammation; Intestinal microflora; intestinal permeability; Intestine; Liver; Liver diseases; metabolic disease; Metabolism; Metabolites; Mice; Microbiota; Morphology; Nicotinamide; Non-alcoholic Fatty Liver Disease - metabolism; Nutrients; Oxidation; Pathogenesis; Permeability; Players; SCFAs; Small intestine; SCFAs; intestinal permeability; metabolic disease; gut-liver axis; gut microbiota
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232213675

The gut is a selective barrier that not only allows the translocation of nutrients from food, but also microbe-derived metabolites to the systemic circulation that flows through the liver. Microbiota dysbiosis occurs when energy imbalances appear due to an unhealthy diet and a sedentary lifestyle. Dysbiosis has a critical impact on increasing intestinal permeability and epithelial barrier deterioration, contributing to bacterial and antigen translocation to the liver, triggering non-alcoholic fatty liver disease (NAFLD) progression. In this study, the potential therapeutic/beneficial effects of a combination of metabolic cofactors (a multi-ingredient; MI) (betaine, N-acetylcysteine, L-carnitine, and nicotinamide riboside) against NAFLD were evaluated. In addition, we investigated the effects of this metabolic cofactors' combination as a modulator of other players of the gut-liver axis during the disease, including gut barrier dysfunction and microbiota dysbiosis. Diet-induced NAFLD mice were distributed into two groups, treated with the vehicle (NAFLD group) or with a combination of metabolic cofactors (NAFLD-MI group), and small intestines were harvested from all animals for histological, molecular, and omics analysis. The MI treatment ameliorated gut morphological changes, decreased gut barrier permeability, and reduced gene expression of some proinflammatory cytokines. Moreover, epithelial cell proliferation and the number of goblet cells were increased after MI supplementation. In addition, supplementation with the MI combination promoted changes in the intestinal microbiota composition and diversity, as well as modulating short-chain fatty acids (SCFAs) concentrations in feces. Taken together, this specific combination of metabolic cofactors can reverse gut barrier disruption and microbiota dysbiosis contributing to the amelioration of NAFLD progression by modulating key players of the gut-liver axis.